TRIM24 and cancer: The data were confirmed by Ogawa-Momohara et al. The frequency of cancer was also higher in patients with the co-occurrence of anti-TIF1-γ and anti-TIF1-ɑ compared to the group with isolated anti-TIF1-γ antibodies (70% vs 64%, respectively) [43].